3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Neurofibroma, Plexiform
3
Neurofibromatosis 1
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Radiation Fibrosis Syndrome
1
Precancerous Conditions
1
Pneumonia
1
Neurofibromatoses
1
Nerve Sheath Neoplasms
1
Neoplasms
1
Myofibroma
1
Lymphedema
1
Leiomyoma
1
Colorectal Neoplasms
1
Acute Lung Injury
1
Interventions
Manual Lymphatic Drainage
10
Exercise
10
Low-Level Light Therapy
6
Standard of Care
4
Physical Therapy Modalities
4
Exercise Therapy
4
Acupuncture Therapy
4
Resistance Training
3
Methods
3
Indocyanine Green
3
Compression Bandages
3
pycnogenols
2
Yoga
2
Technetium Tc 99m Sulfur Colloid
2
Radiotherapy
2
Pentoxifylline
2
Lipectomy
2
High-Energy Shock Waves
2
Early Intervention, Educational
2
Control Groups
2
Bupivacaine
2
Bevacizumab
2
specific substance maruyama
1
pirfenidone
1
pazopanib
1
carbohydrate-deficient transferrin
1
Wound Closure Techniques
1
Weights and Measures
1
Weight Reduction Programs
1
Vitamin E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphedema
×
pirfenidone
×
Clear all
NCT04243837
2024-04-23
LYT-100 in Patients With BCRL
PureTech
Phase 2
Terminated
50 enrolled
9 charts